Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia

Internal Medicine Journal

Volumn 44, Issue 8, 2014, Pages 757-763

  Fedele, P L ^a   Avery, S ^a   Patil, S ^a   Spencer, A ^a   Haas, M ^b   Wei, A ^a,c  

^a ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Acute myeloid leukaemia; Cost effectiveness; Cytarabine; HiDAC

Indexed keywords

CYTARABINE; ETOPOSIDE; IDARUBICIN; ANTINEOPLASTIC ANTIMETABOLITE;

ACCOUNTING; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; AUSTRALIA; BLOOD BANK; CANCER CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONSOLIDATION CHEMOTHERAPY; DRUG COST; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HEALTH ECONOMICS; HEALTH IMPACT ASSESSMENT; HOSPITAL BED UTILIZATION; HOSPITAL DISCHARGE; HOSPITAL POLICY; HOSPITALIZATION COST; HUMAN; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; OUTPATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADOLESCENT; DOSE RESPONSE; ECONOMICS; FOLLOW UP; HEALTH CARE COST; HEALTH CARE PLANNING; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; REMISSION; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; VICTORIA; YOUNG ADULT;

EID: 84905157915     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12478     Document Type: Article

References (29)

1. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Shulman P etal. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896-903.
2. Fernandez H, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM etal. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361: 1249-1259.
3. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N etal. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated { acute myeloid leukemia: the JALSG AML201 Study. Blood 2011; 117: 2358-2365.
4. Bradstock KF, Matthews JP, Lowenthal RM, Baxter H, Catalano J, Brighton T etal. A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 2005; 105: 481-488.
5. 2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia. Intern Med J 2013; 43: 294-297.
6. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH etal. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649.
7. Australian Government Department of Health and Ageing. National hospital cost data collection, 2012. Round 14 (2009-10) Cost Report Version 6.0x, [accessed 2013 Sep].
8. Heng S-C, Slavin MA, Al-Badriyeh D, Kirsa S, Seymour JF, Grigg A etal. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy. J Antimicrob Chemother 2013; 68: 1669-1678.
9. Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J etal. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 2013; 31: 3360-3368.
10. National blood authority - BloodNet. [cited 2013 Sep 7]. Available from URL: http://www.blood.gov.au/bloodnet
11. Juliusson G, Antunovic P, Derolf A, Lehman S, Möllgård L, Stockelberg D etal. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113: 4179-4187.
12. Weick J, Kopecky K, Appelbaum F, Head DR, Kingsbury LL, Balcerzak SP etal. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996; 88: 2841-2851.
13. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D etal. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 1710-1717.
14. van der Jagt A, Muirhead J, Seymour J, Bradstock K, Paul E, Wei A. Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML. Leukemia 2012; 26: 362-365.
15. Löwenberg B, Pabst T, Vellenga E, van Putten W, Shouten HC, Graux C etal. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011; 364: 1027-1036.
16. Lobo PJ, Powles RL, Hanrahan A, Reynold DK. Acute myeloblastic leukaemia - a model for assessing value for money for new treatment programmes. BMJ 1991; 302: 323-326.
17. Pashko S, Jacobs J, Santorsa J. The cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemia. Clin Ther 1991; 13: 353-360.
18. Marie J, Wdowik T, Bisserbe S, Zittoun R. Cost of complete remission induction in acute myeloblastic leukemia: evaluation of the cost-effectiveness of a new drug. Leukemia 1992; 6: 720-722.
19. Tennvall GR, Persson U, Nilsson B. The economic costs of acute myeloid leukemia in Sweden. Int J Technol Assess Health Care 1994; 10: 683-694.
20. Clavio M, Quintino S, Masoudi B, Carrara S, Cerri R, Peirri I etal. Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens. J Exp Clin Cancer Res 2001; 20: 165-173.
21. Nerich V, Lioure B, Rave M, Rechner C, Pigneux A, Witz B etal. Induction-related cost of patients with acute myeloid leukaemia in France. Int J Clin Pharm 2011; 33: 191-199.
22. Mahmoud D, Skikne BS, Kucmin-Bemelmans I, Alleman C, Hensen M. Overall economic burden of total treatment costs in acute myeloid leukemia throughout the course of the disease [abstract]. In: 54th American Society of Haematology Annual Meeting and Exposition; 2012 Dec 10; Atlanta, DC. Blood 2012 120: Abstract 3614.
23. Leunis A, Blommestein HM, Huijgens PC, Blijlevens N, Jongen-Lavrencic M, Uyl-de Groot CA. The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands. Leuk Res 2013; 37: 245-250.
24. Redaelli A, Botteman MF, Stephens JM, Brandt S, Pashos CL. Economic burden of acute myeloid leukemia: a literature review. Cancer Treat Rev 2004; 30: 237-247.
25. Møller T, Nielsen OJ, Welinder P, Dünweber A, Hjerming M, Moser C etal. Safe and feasible outpatient treatment following induction and consolidation chemotherapy for patients with acute leukaemia. Eur J Haematol 2010; 84: 316-322.
26. Savoie ML, Nevil TJ, Song KW, Forrest DL, Hogge DE, Nantel SH etal. Shifting to outpatient management of acute myeloid leukemia: a prospective experience. Ann Oncol 2006; 17: 763-768.
27. Walter RB, Lee SJ, Gardner KM, Chai X, Shannon-Dorcy K, Appelbaum FR etal. Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study. Haematologica 2011; 96: 914-917.
28. AIHW. Australian Institute of Health and Welfare Australasian Association of Cancer Registries - cancer in Australia: an overview, 2008. Cancer Series 2008; 46.
29. Willemze R, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJ etal. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 Trial. J Clin Oncol 2014; 32: 219-228.